{"id":17115,"name":"ExSight Ventures","slug":"exsight-ventures","website":"https://www.exsightventures.com/","hqGeo":"New York, New York","stageFocus":["Pre-Seed","Seed","Series A","Series B"],"sectorTags":[],"excludedSectors":[],"checkSizeMin":null,"checkSizeMax":null,"thesisSummary":"ExSight invests in early-stage companies that are developing breakthrough technologies to aid, diagnose, and treat large populations of those afflicted with vision diseases.","thesisNarrative":null,"logoUrl":null,"aumUsd":null,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"ELIOS Vision, Inc.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Implant-free, minimally invasive glaucoma surgery option.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Re-Vana Therapeutics, Ltd.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Horizon Surgical Systems","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Microsurgery technologies using robotics, medical imaging, and AI.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"DTx Pharma","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Trefoil Therapeutics, Inc.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developing compounds to treat corneal dystrophies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Qura, Inc.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Envision Diagnostics, Inc.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"2C Tech Corporation, Inc.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ONL Therapeutics, Inc.","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developing therapies for retinal diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RetroSense Therapeutics, LLC","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"LensGen","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Ophthalmic device company.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Valitor Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developing medicines using a multivalent biopolymer platform.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Novai","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Biotech developing an AI-supported retinal biomarker for glaucoma and AMD clinical trials.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RevOpsis Therapeutics","companyUrl":null,"stage":"Not specified","sector":"Ophthalmology / biotech","investmentYear":null,"description":"Biopharmaceutical company developing next-generation therapies for retinal diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"DefEYE, Inc.","companyUrl":null,"stage":"Seed","sector":"Ophthalmology / medtech","investmentYear":null,"description":"Ocular company focused on personalized therapeutic approaches in eye care.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"InflammX Therapeutics","companyUrl":null,"stage":"Clinical stage","sector":"Biotech / ophthalmology-adjacent","investmentYear":null,"description":"Clinical-stage biotech developing therapies targeting the NLRP3 inflammasome pathway.","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":3,"partners":[{"id":55754,"name":"James C. Murray, J.D.","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":55755,"name":"Dr. Michael Nissen","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":55756,"name":"Dr. Firas M. Rahhal","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[],"contentUpdatedAt":null,"investorType":"vc","preferredApproach":null,"prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"series-a","displayName":"Series A Investors","pageType":"stage"},{"slug":"series-b","displayName":"Series B Investors","pageType":"stage"}],"fundraisingResources":[{"slug":"how-many-investors-should-you-pitch","title":"How Many Investors Should You Pitch? The Math Most Founders Get Wrong"},{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-11-20T16:15:20.614Z"}